Literature DB >> 16039021

Investigation of non-typeable Haemophilus influenzae outer membrane protein P6 as a new carrier for lipooligosaccharide conjugate vaccines.

Tinghuai Wu1, Jing Chen, Timothy F Murphy, Bruce A Green, Xin-Xing Gu.   

Abstract

Non-typeable Haemophilus influenzae (NTHi) outer membrane protein P6 was used as a new protein carrier for NTHi detoxified lipooligosaccharide (dLOS) conjugates due to its conservation and potential to elicit bactericidal antibodies. P6 was covalently conjugated to dLOS of strain 9274 through adipic acid dihydrazide with different ratios of dLOS to P6, which resulted in two conjugate formulations with weight ratios of dLOS to P6 of 3.7 for dLOS-P6 (I) and 1.6 for dLOS-P6 (II). Binding activity of the conjugates was examined by an enzyme-linked immunosorbent assay with mouse monoclonal antibodies specific to LOS and P6 and a rabbit anti-P6 serum. The results showed that the conjugates bound not only to the LOS antibody but also to both P6 antibodies, suggesting that the conjugates retained epitopes of both LOS and P6 antigens. Animal studies revealed that dLOS-P6 (II) induced high levels of anti-LOS and anti-P6 IgGs in mice and rabbits. However, dLOS-P6 (I) induced lower levels of anti-LOS IgGs in mice and rabbits and anti-P6 IgGs in rabbits with no anti-P6 IgGs in mice. In addition, all rabbit, but not mouse, antisera elicited by the conjugates showed bactericidal activity against the homologous strain, and two of them elicited by each conjugate plus Ribi adjuvant showed cross-bactericidal activity against three of five major serotype stains. These data indicate that P6 could serve as an effective carrier for dLOS or other carbohydrate conjugates and that the ratio of carbohydrate to P6 might contribute to immune responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039021     DOI: 10.1016/j.vaccine.2005.06.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Clin Vaccine Immunol       Date:  2006-10-04

2.  Naturally Acquired HMW1- and HMW2-Specific Serum Antibodies in Adults and Children Mediate Opsonophagocytic Killing of Nontypeable Haemophilus influenzae.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Clin Vaccine Immunol       Date:  2015-10-28

Review 3.  Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.

Authors:  Timothy F Murphy
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

4.  Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease.

Authors:  Charles S Berenson; Catherine T Wrona; Lori J Grove; Jane Maloney; Mary Alice Garlipp; Paul K Wallace; Carleton C Stewart; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

5.  Antibodies to the HMW1/HMW2 and Hia adhesins of nontypeable haemophilus influenzae mediate broad-based opsonophagocytic killing of homologous and heterologous strains.

Authors:  Linda E Winter; Stephen J Barenkamp
Journal:  Clin Vaccine Immunol       Date:  2014-02-26

6.  VapC-1 of nontypeable Haemophilus influenzae is a ribonuclease.

Authors:  Dayle A Daines; Mack H Wu; Sarah Y Yuan
Journal:  J Bacteriol       Date:  2007-05-11       Impact factor: 3.490

7.  Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae.

Authors:  Timothy F Murphy
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725

8.  Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice.

Authors:  Sandro Roier; Deborah R Leitner; Jeremy Iwashkiw; Kristina Schild-Prüfert; Mario F Feldman; Georg Krohne; Joachim Reidl; Stefan Schild
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

9.  The role of TLR2 and bacterial lipoprotein in enhancing airway inflammation and immunity.

Authors:  Amit A Lugade; Paul N Bogner; Timothy F Murphy; Yasmin Thanavala
Journal:  Front Immunol       Date:  2011-04-27       Impact factor: 7.561

Review 10.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.